Ferrante Karen Jean 4

What Happened Karen Jean Ferrante, a director of Cogent Biosciences (COGT), was granted a derivative equity award representing 627 option shares on July 1, 2026. The Form 4 reports the acquisition as a derivative grant at $0.00 (no cash paid by the reporting person). This was an award issued in lieu of regular cash director compensation.

Key Details

• Transaction date: 2026-07-01 (Grant/Award of 627 option shares).
• Consideration reported: $0.00 (derivative award; the reporting person did not pay cash).
• Filing date (Form 4): 2026-07-06 — appears to be filed after the typical 2-business-day reporting window for Form 4s.
• Footnote: Ferrante elected to receive options instead of cash under the issuer’s non-employee director compensation plan; the number of options was calculated by dividing the cash compensation by the Black‑Scholes value of a single option on the grant date.
• Shares owned after the transaction: not specified in the provided filing excerpt.

Context This is a routine director compensation grant (an option award), not an open‑market purchase or sale. Such in-lieu-of-cash option awards are common and reflect compensation method rather than a direct buy or sell signal. Because this is a derivative grant, it does not indicate an immediate sale or cashless exercise of shares. The apparent late filing is procedural — late Form 4s can attract SEC attention or require explanations, but do not by themselves indicate a trading signal.